Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration
Syros Pharmaceuticals, Inc. (
NASDAQSYRS) (the “Company”) today announced that its Board of Directors (the “Board”) has approved and the Company intends to proceed with the voluntary delisting of its common stock from the Nasdaq Stock Market (“Nasdaq”) and the deregistration of its common stock in order to terminate and suspend the Company’s reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act").
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
Syros Pharmaceuticals, Inc. (
NASDAQSYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to tamibarotene for the treatment of higher-risk myelodysplastic syndrome (HR-MDS). Tamibarotene, an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, is currently being evaluated in combination with azacitidine for the treatment of newly diagnosed HR-MDS patients with RARA gene overexpression.
Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
Syros Pharmaceuticals, Inc. (
NASDAQSYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of its merger with Tyme Technologies, Inc., pursuant to which Syros acquired TYME, including its pipeline assets and net cash at closing of approximately $60 million. Shares of the combined company will trade on Nasdaq under the ticker symbol “SYRS.”
Syros and Tyme Technologies Announce Stockholder Approval of Merger
Syros Pharmaceuticals, Inc. (
NASDAQSYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc.
NASDAQ:TYMENASDAQTYME)
Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer
Syros Pharmaceuticals, Inc. (
NASDAQSYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SY-5609 for the treatment of pancreatic cancer. SY-5609, a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, is currently being evaluated in combination with chemotherapy for the treatment of patients with relapsed metastatic pancreatic cancer.
